- Home
- COLL
as 01-17-2025 4:00pm EST
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | STOUGHTON |
| Market Cap: | 1.1B | IPO Year: | 2015 |
| Target Price: | $43.80 | AVG Volume (30 days): | 486.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.16 | EPS Growth: | 757.11 |
| 52 Week Low/High: | $28.39 - $42.29 | Next Earning Date: | 02-20-2025 |
| Revenue: | $599,245,000 | Revenue Growth: | 9.62% |
| Revenue Growth (this year): | 13.2% | Revenue Growth (next year): | 17.63% |
Latest Collegium Pharmaceutical Inc. News
COLL Breaking Stock News: Dive into COLL Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Collegium Pharmaceutical Insider Sold Shares Worth $908,628, According to a Recent SEC Filing
MT Newswires
9 days ago
Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46
TipRanks
10 days ago
Collegium Pharmaceutical Unveils 2025 Financial Projections
MT Newswires
10 days ago
Collegium Pharmaceutical Shares Rise After 2025 Guidance
GlobeNewswire
11 days ago
Collegium Provides 2025 Financial Guidance and Business Update
Simply Wall St.
25 days ago
Pulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focus
Argus Research
a month ago
COLL: Lowering target price to $31.00
Argus Research
a month ago
COLL: What does Argus have to say about COLL?
Compare COLL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COLL Collegium Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.